Bank of New York Mellon’s Fulcrum Therapeutics FULC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$566K Buy
154,513
+4,571
+3% +$27.8K ﹤0.01% 3685
2026
Q1
$1.15M Buy
149,942
+33,036
+28% +$306K ﹤0.01% 3124
2025
Q4
$1.32M Sell
116,906
-2,252
-2% -$22.9K ﹤0.01% 3081
2025
Q3
$1.1M Sell
119,158
-17,842
-13% -$129K ﹤0.01% 3162
2025
Q2
$943K Sell
137,000
-6,588
-5% -$35.2K ﹤0.01% 3157
2025
Q1
$414K Buy
143,588
+1,715
+1% +$6.3K ﹤0.01% 3545
2024
Q4
$667K Buy
141,873
+3,126
+2% +$11.5K ﹤0.01% 3373
2024
Q3
$495K Sell
138,747
-47,980
-26% -$356K ﹤0.01% 3523
2024
Q2
$1.16M Buy
+186,727
New +$1.41M ﹤0.01% 3112
2024
Q1
Sell
-19,831
Closed -$134K 4215
2023
Q4
$134K Sell
19,831
-41,359
-68% -$184K ﹤0.01% 4036
2023
Q3
$272K Sell
61,190
-1,132
-2% -$4.95K ﹤0.01% 3851
2023
Q2
$206K Sell
62,322
-149,879
-71% -$440K ﹤0.01% 3970
2023
Q1
$605K Buy
212,201
+14,345
+7% +$129K ﹤0.01% 3389
2022
Q4
$1.44M Buy
197,856
+65,383
+49% +$426K ﹤0.01% 3020
2022
Q3
$1.07M Buy
132,473
+28,053
+27% +$201K ﹤0.01% 3174
2022
Q2
$512K Buy
104,420
+3,781
+4% +$36.9K ﹤0.01% 3566
2022
Q1
$2.38M Sell
100,639
-31
-0% -$439 ﹤0.01% 2832
2021
Q4
$1.78M Buy
100,670
+5,639
+6% +$112K ﹤0.01% 3063
2021
Q3
$2.68M Buy
95,031
+31,059
+49% +$589K ﹤0.01% 2823
2021
Q2
$670K Buy
63,972
+21,725
+51% +$220K ﹤0.01% 3632
2021
Q1
$497K Sell
42,247
-765
-2% -$9.46K ﹤0.01% 3692
2020
Q4
$504K Buy
43,012
+6,457
+18% +$73K ﹤0.01% 3613
2020
Q3
$291K Buy
36,555
+4,641
+15% +$55.9K ﹤0.01% 3731
2020
Q2
$583K Sell
31,914
-1,389
-4% -$21.9K ﹤0.01% 3401
2020
Q1
$398K Buy
+33,303
New +$533K ﹤0.01% 3484

Other funds holding FULC

Bank of New York Mellon's FULC Position: Q2 2026 in Review

Bank of New York Mellon increased its Fulcrum Therapeutics (FULC) stake by 3% in Q2 2026, buying an estimated $27.8K and bringing the position to 154,513 shares worth $566K. The position accounts for ﹤0.01% of the portfolio, ranked #3685.

Bank of New York Mellon first reported a position in FULC in Q1 2020 and has held it in 25 quarters since. The position peaked at $2.68M in Q3 2021. 50 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • Bank of New York Mellon held 154,513 shares of Fulcrum Therapeutics worth $566K as of Q2 2026.
  • Bank of New York Mellon bought 4,571 Fulcrum Therapeutics shares in Q2 2026, an estimated $27.8K.
  • Fulcrum Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3685 holding.
  • Bank of New York Mellon first reported a position in Fulcrum Therapeutics in Q1 2020 and has held it in 25 quarters since.
  • Bank of New York Mellon's Fulcrum Therapeutics position peaked at $2.68M in Q3 2021.
  • 50 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.